Table 4.

Study endpoints

Primary outcome	Slope of eGFR over 24 months
Secondary outcomes	Graft and patient survival at 24 months
	Measured GFR (Cr-51-EDTA method) at 24 months
	DSA at 6, 12, 18, and 24 months
	Mean fluorescence intensity levels
	Number of human leukocyte antigen specificities
	Urinary protein excretion (protein/creatinine ratio) at 6, 12, 18, and 24 months
	Occurrence of biopsy-proven acute rejection necessitating rejection treatment
	Acute AMR score in a protocol biopsy performed at 24 months
	Chronic AMR score in a protocol biopsy performed 24 months

AMR, antibody-mediated rejection; Cr-51-EDTA, chromium ethylenediamine tetraacetic acid; DSA, donor-specific antibodies; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate.